This guidance is for companies wishing to apply for a contract through the Antimicrobial Products Subscription Model. The guidance builds on a joint pilot project between NICE and NHS England which is the first in the world to pay companies a fixed annual fee for antimicrobials based on their value to the NHS, as opposed to the volumes used. This was further informed by a consultation on proposals for the subscription model in July to October 2023. A consultation summary is available in the thematic analysis report.

The subscription model uses the standard NHS procurement process and is advertised on the GOV.UK Find A Tender service.

For other therapeutic areas, the NHS commercial framework for new medicines outlines how pharmaceutical companies can engage with the NHS.

For further information about the ambitions and actions supporting the 20-year vision for antimicrobial resistance (AMR), please see the UK 5-year action plan for antimicrobial resistance 2024 to 2029 (this is the UK’s second national action plan, following the UK 5-year action plan for antimicrobial resistance 2019 to 2024).